News

Proteome Sciences and Millipore have signed an exclusive license agreement to develop new products that will help to advance the study of Alzheimer’s disease. Under the terms of

The US Patent and Trademark Office (PTO) is re-examining two currently issued US patents owned by the Institute Pasteur and the Universite Pierre et Marie Curie, and licensed

OXiGENE, a clinical-stage biopharmaceutical company developing therapeutics to treat cancer and eye diseases, is all set to acquire all of the equity of Symphony ViDA, in exchange for

Avanir has announced that the open label extension of the confirmatory phase III STAR trial is now fully enrolled. The primary objective of the study is to assess

McKesson has renewed its current distribution agreement to supply CVS with branded and generic drugs. Paul Julian, Executive Vice President and Group President, McKesson, said: “CVS’s decision to

Eli Lilly has received a fourth approval from FDA for Alimta (pemetrexed for injection). The latest approval is for Alimta as a maintenance therapy for locally advanced or

Theraclone and the International AIDS Vaccine Initiative (IAVI) have expanded their HIV antibody discovery program. Under the terms of the agreement, Theraclone would receive additional funding from IAVI

Novartis has delivered the 250 millionth treatment of Coartem, an artemisinin-based combination therapy (ACT) for the treatment of malaria. The 250,000,000th treatment was delivered to healthcare clinic in

Celtic Pharma Holdings Advisors (CPHA), the advisor to the second Celtic pharma fund, Celtic Pharma Holdings II LP (CP2), would invest in a majority shareholding in Novacta Biosystems